Host-microbiome interactions in nicotinamide mononucleotide (NMN) deamidation

Kim LJ, Chalmers TJ, Madawala R, Smith GC, Li C, Das A, et al. | FEBS Lett | 2023 | Evidence: limited

Plain-language summary

Published 2023 in FEBS Lett, this work by Kim LJ and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

Mechanistic study in FEBS Lett (2023) on NAD+/sirtuin/longevity biology
Adds to the foundational literature underlying NMN supplementation rationale
First author: Kim LJ

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

← Back to research index